華潤醫藥(03320.HK)2021年純利升14.3%至37.69億港元 業績實現恢復性增長
格隆匯3月29日丨華潤醫藥(03320.HK)公佈2021年度業績,期內集團實現收益2368.06億港元,同比增長18.2%,主要受疫情緩解影響,業績實現恢復性增長。2021年製藥、醫藥分銷、藥品零售三個主要業務分部的收益佔比分別為14.9%、81.9%以及3.2%。
報吿期間內,集團實現毛利353.80億港元,同比增長9.6%,毛利率由上年同期的16.1%降至14.9%;公司擁有人應占溢利37.69億港元,同比增長14.3%;每股基本盈利0.6港元,宣派末期股息每股0.15港元。
報吿期間內,集團製藥業務實現分部收益386.14億港元,較2020年增長19.9%。主要因為受疫情緩解影響及外延併購帶動,CHC板塊(主要包含非處方藥及保健品)、處方藥板塊及生物藥板塊收入增長顯著。
報吿期間內,集團醫藥分銷業務實現分部收益1991.25億港元,較2020年增長17.9%。2021年分銷業務毛利率為6.2%,較上年同期下降0.9個百分點,主要由於疫情緩解,毛利率水準較高的防疫物資出口業務收入減少。
報吿期間內,集團醫藥零售業務錄得收益76.05億港元,較2020年同比增加17.6%,主要因為高值藥品直送業務(”DTP“)業務收入增速較快。集團的DTP業務2021年實現收益約43.15億元人民幣,同比增長約12.7%。零售業務毛利率為9.2%,較上年同期比下降1.1個百分點。毛利率水準的下降主要因為毛利率較低的DTP業務收入比重增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.